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Bladder cancera b s t r a c t
LncRNAs have a critical role in the regulation of cellular processes such as cancer progression and
metastasis. In the present study, we confirmed that TUG1 was overexpressed in bladder cancer tis-
sues and established cell lines. Knockdown of TUG1 inhibited bladder cancer cell metastasis both
in vitro and in vivo. Furthermore, we found that TUG1 promoted cancer cell invasion and radiore-
sistance through inducing epithelial-to-mesenchymal transition (EMT). Interestingly, TUG1
decreased the expression of miR-145 and there was a reciprocal repression between TUG1 and
miR-145 in an Argonaute2-dependent manner. ZEB2 was identified as a down-stream target of
miR-145 and TUG1 exerted its function through the miR-145/ZEB2 axis. In summary, our data indi-
cated that blocking TUG1 function may be an effective anti-cancer therapy.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer, the ninth most common cancer worldwide, is a
heterogeneous disease which can be categorized into the low-
grade papillary tumors and the high-grade invasive tumors [1].
Invasive bladder tumor is more aggressive and patients with inva-
sive disease have a much worse prognosis, with a 5-year survival
rate around 50% Despite the recent advances in the early detection
and surgical treatment, the mortality has not changed markedly
[2]. Therefore, it is urgent to clarify the molecular mechanism of
the development of bladder cancer for the advances in novel diag-
nostic marker and therapeutic targets.
It is well documented that protein-coding genes account for
only about 2% of the human genome, whereas the majority of tran-
scripts consist of the non-coding RNAs, including microRNAs andlong non-coding RNAs (lncRNAs) [3]. A body of literature shows
that lncRNAs may serve as master gene regulators capable of con-
trolling protein-coding and non-coding genes. The lncRNAs have
been implicated in the regulation of a variety of cellular functions
and disease processes including cancer metastasis [4]. The poten-
tial function of lncRNAs is to competitively inhibit miRNAs as a
molecular sponge [5]. However, limited knowledge is available
concerning whether lncRNAs affect the biological processes of
epithelial to mesenchymal transition (EMT) by regulating miRNAs.
The aim of the present study was to identify the function of
lncRNA TUG1 in bladder cancer. In addition, we investigated
whether miR-145 mediated this process. Our findings will provide
new insights into the molecular functions of TUG1 as well as its
regulatory mechanisms in bladder cancer.
2. Materials and methods
2.1. Patient samples and cell lines
All bladder cancer tissues were obtained from Affiliated Tumor
Hospital of Guangzhou Medical University. Specimens were
formalin-fixed and embedded in paraffin by standard methodology
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written consent for their tissue samples to be used for research pur-
poses (detailed patients’ clinical-pathological parameters can be
seen in Supplement Table 1). This study was approved by the Ethi-
cal and Scientific Committees of Guangzhou Medical University.
Human bladder cell lines and normal bladder cell line SV-HUC-1
were obtained from the Institute of Biochemistry and Cell Biology
of the Chinese Academy of Sciences (Shanghai, China). All cell lines
were maintained in a humid wet atmosphere containing 5% CO2 at
37 C in RPMI-1640 medium supplemented with 10% newborn
bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin.
2.2. RNA isolation and quantitative real-time PCR
Total RNA was extracted with TRIzol reagent (Invitrogen, Carls-
bad, California, USA). For qPCR, RNA was reverse transcribed to
cDNA from 1 lg of total RNA using a Reverse Transcription Kit
(Takara). Real-time PCR analyses were conducted with Power SYBR
Green (Takara). Results were normalized to the expression of U6 or
GAPDH. The primers for TUG1 and miR-145 were previously
described [6,7]. The primers for U6 were 50-CTCGCTTCGGCAG
CACA-30 (forward) and 50-AACGCTTCACGAATTTGCGT-30 (reverse).
The primers for GAPDH were 50-AACGTGTCAGTGGTGGACCTG-30
(forward) and 50-AGTGGGTGTCGCTGTTGAAGT-30 (reverse). The
relative expression of each gene was calculated and normalized
using the 244Ct method relative to U6 snRNA or GAPDH.
2.3. LncRNA profiler and detection
Disease-Related Human LncRNA Profiler (Cat. #RA920) was
purchased from system biosciences. The detection of lncRNA was
performed according to the instructions.
2.4. Cell invasion assay and clonogenic assay
For cell invasion assays, the cell suspended in serum free RPMI-
1640 medium were seeded on a fibronectin coated polycarbonate
membrane, which was precoated with Matrigel. The polycarbonate
membrane were inserted in a transwell apparatus. In the lower
chamber, RPMI-1640 with 10% newborn bovine serum added as a
chemoattractant. Cells adhering to the lower surface were fixed
with methanol, stained with Giemsa solution and counted under
a microscope in five predetermined fields.
For clonogenic assay, the cells were seeded in 6-well plates and
were incubated for 24 h. Then the cells were treated with a range of
IR doses (0, 2, 4, 6 and 8 Gy, Nasatron (Cs-137) irradiator). The colo-
nies were stained with crystal violet solution 14 days later. Plate
clone formation efficiency = (number of colonies/number of cells
inoculated)  100%. Survival fractions (SF) were calculated by nor-
malization to the plating efficiency of appropriate control groups.
2.5. Lentivirus production and transduction
Lentiviral shRNA targeting TUG1 was designed at http://bioset-
tia.com/support/shrna-designer and cloned into pLV-H1TetO-GFP-
Puro vector according to manufacturer’s instructions (Biosettia).
The viruses were packaged in 293T cells according to standard pro-
tocols and the virus particles were harvested 72 h later. The pack-
aged lentiviruses were named sh-TUG1 and the empty lentiviral
vector sh-ctrl was used as a control. Cells were infected with virus
particles plus 8 lg/ml Polybrene.
2.6. Oligonucleotide transfection
Synthesized RNA duplexes of miRNA control, miR-145 and
anti-miR-145 were obtained from Ribobo (Guangzhou, China).pcDNA3-ZEB2 was purchased from Biosettia Inc. (Biosettia, San
Diego, USA). Oligonucleotide transfection was performed with
Lipofectamine 2000 reagent (Invitrogen).
2.7. Luciferase reporter assay
The 30-UTR untranslated region of ZEB2 was amplified by PCR
and cloned downstream of the firefly luciferase gene in the pGL3
vector (Promega). The vector was named ZEB2–30-UTR. Cells were
transfected with ZEB2–30-UTR and miR-ctrl or miR-145. The luci-
ferase assay was performed by using the dual Luciferase reporter
assay system (Promega) 48 h after transfection.
2.8. Western blot assay
Western blot assay was performed as previously described [8].
Briefly, equal amounts of protein were resolved by SDS–PAGE and
transferred to polyvinylidene fluoride (PVDF) membrane. Then the
membranes were blocked in 5% non-fat skim milk/TBST, followed
by detected with primary antibodies at 4 C overnight. Subse-
quently, the membranes were detected with appropriate sec-
ondary antibodies. The levels of goal protein were detected with
enhanced chemiluminescence reagents (Pierce, Rockford, IL). The
primary antibodies E-cadherin, N-cadherin, Vimentin and GAPDH
were purchased from Santa Cruz (USA).
2.9. RNA-binding protein immunoprecipitation (RIP) assay
RNA-binding protein immunoprecipitation (RIP) assay was per-
formed using the EZ-Magna RIP Kit (Millipore, Billerica, MA, USA)
according to the manufacturer’s instruction. Briefly, cells were
lysed with the use of RIP lysis buffer, followed by incubated with
RIP buffer containing magnetic beads conjugated with human
anti-Ago2 antibody (Millipore) or negative control Normal Mouse
IgG (Millipore). Proteinase K was used to digest the protein and
then immunoprecipitated RNA was isolated. NanoDrop spec-
trophotometer was used to measure the RNA concentration. Puri-
fied RNA was subjected to q-RT-PCR analysis.
2.10. In vivo study
The experimental metastasis studies were conducted as previ-
ously described [9]. The cells were injected into the mice via the
tail vein. Six weeks later, the mice were sacrificed and lung metas-
tases were detected using H&E staining.
2.11. Statistical analysis
SPSS 16.0 and Graph Pad Prism 5.0 software were used for sta-
tistical analysis. Data are represented as mean ± S.E.M. Fischer’s
were used to identify differences between categorical variables.
One-way ANOVA or two-tailed Student’s t-test was used for com-
parisons between groups. Differences were considered statistically
significant when P < 0.05.3. Results
3.1. TUG1 expression was up-regulated in bladder cancer tissues and
cell lines
Using a Disease-Related Human LncRNA Profiler, we identified
several lncRNAs that were significantly increased in bladder cancer
tissues (Supplement Table 2). We chose TUG1 for further study,
because its expression was the highest among these lncRNAs in
the bladder cancer tissues (Fig. 1A, P < 0.05). Interestingly, TUG1
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lines than in normal human bladder cell line SV-HUC-1 (Fig. 1B,
P < 0.05).
To further study the relationship of TUG1 with clinicopatholog-
ical characteristics in bladder cancer patients, the expression of
TUG1 was detected in 54 clinical patients using real-time PCR. It
was found that the higher level expression of TUG1 was associated
with worse pTNM stage (Fig. 1C, P < 0.05). We also found that
patientswith higher expression of TUG1had shorter overall survival
time than those with lower expression of TUG1 (Fig. 1D, P < 0.05).
3.2. TUG1 promoted bladder cancer cells invasion and radioresistance
through inducing EMT
We then explored the potential impact of TUG1 on bladder can-
cer cell invasion. We first established T24 and UMUC3 cells stably
knocked down of TUG1 and these cells were named sh-TUG1 (Sup-
plementary Fig. 1A, P < 0.05). Those cells treated with negative
control were named sh-ctrl. The invasion assay showed that
knockdown of TUG1 significantly inhibited the invasion of T24
cells compared with the control (Fig. 2A). Interestingly, knock-
down of TUG1 also increased T24 cells to ionizing radiation
(Fig. 2B). Since EMT is well known to be involved in invasion
and radioresistance of cancer cells, we asked whether TUG1 pro-
moted cancer cell invasion through regulating EMT. We assessed
the EMT markers by western blot in sh-TUG1 cells and control
cells. Interestingly, we found that the expression level of epithelial
marker (i.e., E-cadherin) increased, while the levels of mesenchy-
mal markers (i.e., N-cadherin and vimentin) decreased, when
TUG1 was inhibited in T24 cells (Fig. 2C). We found that knock-
down of TUG1 also decreased invasion and reversed EMT in
UMUC3 cells (Supplementary Fig. 1B and C, P < 0.05). The
Immunofluorescence staining was also parallel to the western blot
assay (Fig. 2D). These data suggested that knockdown of TUG1
reversed EMT in bladder cancer cells.Fig. 1. TUG1 expression was up-regulated in bladder cancer tissues and cell lines. (A) T
higher levels in a panel of 4 human bladder cancer cell lines than in normal human bladde
pTNM stage in bladder cancer patients. (D) Bladder cancer patients with higher express
TUG1.3.3. Reciprocal repression between TUG1 and miR-145
A body of literatures suggested that lncRNAs might participate
in competing endogenous RNA (ceRNA) regulatory networks [10],
suggesting that there might be an inverse correlation between
expression of lncRNA and miRNA. We thus asked whether micro-
RNAs mediated TUG1’s function in regulating EMT. Using bioinfor-
matics databases (miRanda), TUG1 was predicted to harbor miR-
145 binding sites (Fig. 3A). To further investigate whether TUG1
was a functional target of miR-145, we cloned reporter plasmid
containing the predicted miR-145 binding site (TUG1-Wt) and
plasmid that the miR-145 seed region binding site was mutated
(TUG1-Mut). The results showed that co-transfection of mature-
miR-145 and TUG1-Wt strongly decreased the luciferase activity,
while co-transfection of miR-NC and TUG1-Wt did not change
the luciferase activity. Interestingly, co-transfection of mature-
miR-145 and TUG1-Mut did not change the luciferase activity
either (Fig. 3B, P < 0.05). We next assessed whether miR-145 was
able to negatively regulate TUG1 expression. As shown in Fig. 3C,
the TUG1 expression was decreased in pre-miR-145 groups,
whereas that in anti-miR-145 group was increased (P < 0.05).
Taken together, these data suggested that miR-145 could directly
bind to TUG1 and negatively regulated TUG1 expression.
To determine whether miR-145 is regulated by TUG1, we
detected the expression of miR-145 after knockdown of TUG1.
The results showed that the miR-145 expression was increased
in sh-TUG1 groups compared with sh-ctrl groups (Fig. 3D, P < 0.05).
It is documented that miRNAs exert their gene silencing func-
tions through a ribonucleoprotein complex called the RNA induced
silencing complex (RISC). The core component of the RISC was
Ago2 [11]. RIP experiments were performed to determine whether
TUG1 and miR-145 are in the same RISC complex. Quantitative RT-
PCR was used to determine RNA levels in immunoprecipitates. We
found that TUG1 and miR-145 were enriched in Ago2 immunopre-
cipitates relative to control IgG immunoprecipitates (Fig. 3E,UG1 expression was elevated in the bladder cancer tissues. (B) TUG1 expressed at
r cell line SV-HUC-1. (C) Higher level expression of TUG1 was associated with worse
ion of TUG1 had shorter overall survival time than those with lower expression of
Fig. 2. TUG1 promoted bladder cancer cells invasion through inducing EMT. (A) Knockdown of TUG1 significantly inhibited the invasion of T24 cells. (B) Knockdown of TUG1
increased radiosensitivity of T24 cells. (C) The expression level of epithelial marker (i.e., E-cadherin) increased, while the levels of mesenchymal markers (i.e., N-cadherin and
vimentin) decreased in T24 cells stably knockdown of TUG1. (D) The immunofluorescence assay was carried out to determine the expression level of E-cadherin, N-cadherin
and vimentin.
Fig. 3. Reciprocal repression between TUG1 and miR-145. (A) The binding sites of miR-145 on TUG1. (B) Co-transfection of miR-145 and TUG1-Wt strongly decreased the
luciferase activity, while co-transfection of miR-NC and TUG1-Wt did not change the luciferase activity. Co-transfection of miR-145 and TUG1-Mut did not change the
luciferase activity either. (C) MiR-145 negatively regulated TUG1 expression. (D) Knockdown of TUG1 increased miR-145 expression. (E) TUG1 and miR-145 were enriched in
Ago2 immunoprecipitates relative to control IgG immunoprecipitates.
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probably in the same RISC complex, consistent with our bioinfor-
matic analysis and luciferase assays.
3.4. MiR-145/ZEB2 axis mediated the effect of TUG1 on EMT in bladder
cancer cells
Since miR-145 was involved in EMT process in cancer cells [12],
we asked whether the effect of TUG1 on cell invasion wasmediated by miR-145. Fig. 4A showed that knockdown of TUG1
significantly inhibited the invasion of T24 cells, while anti-miR-
145 treatment rescued the effect. In addition, the alter of EMT
related markers, caused by TUG1 down-regulation, were also res-
cued by anti-miR-145 treatment (Fig. 4B). These results strongly
suggested that miR-145 played a crucial role in TUG-1-induced
EMT in bladder cancer cells.
MicroRNAs influenced biological activity by regulating its
down-stream targets [13]. ZEB2, a master inducer of EMT [14],
Fig. 4. MiR-145/ZEB2 axis mediated the effect of TUG1 on EMT in bladder cancer cells. (A) Knockdown of TUG1 significantly inhibited the invasion of T24 cells, while anti-
miR-145 treatment rescued the effect. (B) The alter of EMT related markers, caused by TUG1 down-regulation, were rescued by anti-miR-145 treatment. (C) ZEB2 was
identified as a down-stream target of miR-145. (D) The luciferase assay showed that cells transfected with miR-145 had less luciferase activity than those transfected with
miR ctrl (left panel). MiR-145 repressed ZEB2 protein expression in bladder cancer cells (right panel). (E) Inhibition of TUG1 decreased ZEB2 expression.
Fig. 5. (A) Knockdown of TUG1 inhibited tumor metastasis in vivo. (B) TUG1
expression was inversely correlated with miR-145 expression in bladder cancer
tissues.
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Indeed, the luciferase assay showed that cells transfected with
miR-145 had less luciferase activity than those transfected with
miR ctrl (Fig. 4D, left panel, P < 0.05). The western blot assay
demonstrated that miR-145 repressed ZEB2 protein expression in
bladder cancer cells (Fig. 4D, right panel). In sh-TUG1 cells, we
found that the level of ZEB2 was less than that in sh-ctrl cells(Fig. 4E). Interestingly, restoration of ZEB2 rescued knockdown of
TUG1 effect on cell invasion, together with the effect on EMT (Sup-
plement Fig. 2A and B).
Taken together, these data suggest that miR-145/ZEB2 axis
mediated the effect of TUG1 on bladder cancer cell invasion.
3.5. Knock down of TUG1 suppressed tumor metastasis in vivo
EMT is a key step of the progression of tumor cell metastasis
and EMT inhibition may be a way to suppress cancer metastasis.
We investigated whether knock down of TUG1 could inhibited
lung metastasis in vivo. The lung metastasis models were estab-
lished by the tail vein injection of sh-TUG1 cells or sh-ctrl cells.
As shown in Fig. 5A, the tumor nodules were dramatically reduced
in pLKO.1-sh-TUG1 group. This data suggested that knock down of
TUG1 may suppress tumor metastasis in vivo.
3.6. TUG1 expression was inversely correlated with miR-145
expression in bladder cancer tissues
The expressions of TUG1 and miR-145 were examined in 22
bladder cancer patient tissues that were used above. As shown in
Fig. 5B, there was a significant inverse correlation between TUG1
and miR-145 expression levels by Pearson correlation analysis
(R = 0.938, P < 0.05).
4. Discussion
Recent studies have revealed that lncRNAs were found to be
deregulated in several human cancers including bladder cancer
[15,16]. Understanding the molecular mechanism of lncRNAs
may help to explore new promising therapeutic strategy for the
treatment of bladder cancer. LncRNA TUG1 was overexpressed in
several kinds of cancer tissues such as osteosarcoma [17], esopha-
geal carcinoma [18] and B-cell neoplasms [19]. However, TUG1
was down-expressed in non-small cell lung carcinoma [20]. This
reflected varying roles for TUG1 in different cancer types. Inhibi-
tion of IncRNA TUG1 resulted in increased apoptosis in murine
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moted proliferation and migration in vitro [18]. Gezer et al. found
that TUG1 were highly enriched in secreted exosomes of HeLa and
MCF-7 cells [22]. These data suggested that TUG1 may promote
cancer progression. However, whether microRNA mediates the role
of TUG1 on tumor invasion is still unknown.
In the present study, we found that TUG1 was overexpressed in
bladder cancer tissues and established cell lines. Our findings were
consistent with the data from Han et al. [23]. The function of TUG1
was subsequently investigated in our study. The data indicated
that knockdown of TUG1 inhibited bladder cancer cell invasion
both in vitro and in vivo. In addition, our data revealed that knock-
down of TUG1 increased bladder cancer cell radiosensitization.
Furthermore, we found that TUG1 regulated metastasis
through inducing EMT, a key process during cancer invasion
[24,25]. These results suggested that TUG1 act as a tumor gene
in bladder cancer.
Emerging evidence suggests that lncRNAs act as endogenous
miRNA sponges to bind to miRNAs and regulate their function
[26,27]. To find out whether TUG1 serves as a miRNA sponge, we
performed the bioinformatics analysis and found that TUG1 con-
tained binding sites for several miRNAs. During these miRNAs,
we focused on miR-145. MiR-145 is a regulator of EMT during can-
cer progression. MiR-145 is often down-regulated in cancer tissues
and restoration of miR-145 suppressed cancer cell invasion by
reversing the EMT phenotype [12,28]. MiR-145 acts as a tumor
suppressor in bladder cancer [29]. However, the mechanism of
miR-145 down-regulation is still poorly understood. We hypothe-
sized that TUG1 may negatively miR-145 expression and miR-145
was chosen for further study. Luciferase assay indicated that miR-
145 could bind to TUG1 directly by the putative miRNA response
element. Furthermore, overexpression of miR-145 suppressed
TUG1 expression, whereas down-regulated miR-145 induced a
reverse result. Interestingly, knocked down of TUG1 elevated
miR-145 expression. The above data suggested that there might
be a reciprocal repression between TUG1 and miR-145. Finally,
we found that TUG1 and miR-145 were in the same RISC complex
by RIP assays, suggesting that there was a physical interaction in
bladder cancer cells.
We further investigated whether miR-145 mediated the tumor-
suppressive effect of TUG1 knockdown in bladder cancer. Our pre-
sent data indicated that while knockdown of TUG1decreased blad-
der cancer cell invasion ability, inhibiting miR-145 could rescue
the effects that knockdown of TUG1 exerted. ZEB2 was identified
as a direct target of miR-145. The expression of ZEB2 has been
reported in different tumors, including bladder cancer [30,31].
Recent reports highlighted that ZEB2 was closed related to EMT
[32,33], suggesting ZEB2 is a key factor in promoting the initiation
and development of cancer. It was reported that ZEB2 led to the
loss of epithelial marker E-cadherin and disrupt cell-to-cell adhe-
sion. In addition, ZEB2 was able to upregulate mesenchymal mark-
ers, which include N-cadherin and vimentin [34,35]. These data
suggested that ZEB2may be a key mediator of EMT in cancer devel-
opment. Interestingly, ZEB2 could protect cell from radiation-
induced apoptosis in bladder cancer cells [36]. Thus, we proposed
that the ZEB2 regulated EMT and radioresistance in bladder cancer
cells. Our data revealed that TUG1 elevated ZEB2 expression by
negatively regulating miR-145 expression. It is possible that the
miR-145/ZEB2 axis mediated TUG1 function on EMT and
radioresistance.
In summary, our findings confirmed that TUG1 promoted blad-
der cancer cell metastasis and radioresistance. In addition, we
demonstrated that TUG1 negatively regulated miR-145 expression
by acting as a miRNA sponge. Our findings might facilitate the
development of lncRNA-directed diagnostics and therapeutics
against bladder cancer.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.08.
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